AFP and hepatocellular carcinoma: Multivariate analysis after PSM revealed that RFA treatment (HR = 4.05; 95% CI 2.84–5.78; P < 0.001), AFP ≥ 200 ng/mL (HR = 1.12; 95% CI 1.06–1.80; P = 0.048), multiple tumors (HR = 1.94; 95% CI 1.42–2.69; P < 0.001), early recurrent stage (HR = 2.56; 95% CI 1.76–3.75; P < 0.001), primary HCC size ≥ 10 cm (HR = 1.571.5; 95% CI 1.17–2.52; P = 0.035), BCLC B stage (HR = 1.26; 95% CI 1.11–1.76; P = 0.042), MVI positive (HR = 1.43; 95% CI 1.04–1.96; P = 0.028) were associated with poorer OS (Table 3).